Oral Answers to Questions

Clive Efford Excerpts

Thursday 15th March 2018 Commons Chamber

[Mr Baker]

I lament the hon. Gentleman’s continual determination to talk down this country. I am happy to tell him that Unilever has today shown its long-term commitment to the UK by choosing to locate its two fastest-growing global business divisions in this country, safeguarding 7,300 jobs and £1 billion a year of investment. As the company has made clear, its decision to transfer a small number of jobs to a corporate headquarters in the Netherlands is part of its long-term restructuring and is not connected to the UK’s departure from the EU.

[Clive Efford (Eltham) (Lab)]

On the basis that it is subject to negotiation, the Government have refused to implement the agreed replacement to the regime for the inadequate 2004 clinical trial directive. This is essential for our pharmaceutical trade, because we face going off a cliff edge and not being able to participate in collaborative clinical trials with EU research institutions, so when is the Minister going to implement that replacement directive?

[Mr Baker]

As part of exit negotiations, the Government will discuss with the EU and member states how best to continue co-operation in the field of clinical trials. The UK has been working towards implementation of the new European clinical trials regulation since it was agreed in 2014. The application date of the CTR across the EU will be set by the European Commission, and if it is after our exit from the EU, it will not be part of the withdrawal Bill.